Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to determine the efficacy and safety profile of TKI258 in 3 groups of patients with metastatic HER2 negative breast cancer (BC) stratified by FGFR1 and hormone receptor (HR) status.

Official Title
-----------------
A Multi-center, Open Label Phase II Trial of TKI258 in FGFR1 Amplified and Non-amplified Metastatic or Advanced HER2 Negative Breast Cancer

Conditions
-----------------
Metastatic Breast Cancer

Intervention / Treatment
-----------------
* Drug: TKI258


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female presenting with metastatic breast cancer. Tumor must have been tested by FISH/CISH for FGFR1 amplification. HER2 and HR status must have been determined. Patients must have HER2 negative breast cancer. Patients must have a documented disease progression as define by RECIST at baseline. Patients with HR+ disease: Must have received at least one prior endocrine therapy in the metastatic setting. Must have received no more than three lines of chemotherapy in the metastatic setting. Patients with HR- disease must have received at least one and no more than three lines of chemotherapy in metastatic setting. Exclusion Criteria: Patients with known brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Impaired cardiac function or clinically significant cardiac diseases, including any of the following: History or presence of serious uncontrolled ventricular arrhythmias or presence of atrial fibrillation. Clinically significant resting bradycardia (< 50 beats per minute). LVEF assessed by 2-D echocardiogram (ECHO) or Multiple gated acquisition scanning (MUGA)< 45%. Any of the following within 6 months prior to study entry: myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Pulmonary Embolism (PE). Uncontrolled hypertension defined by a SBP > 150mm Hg and/or DBP > 100mm Hg, with or without anti-hypertensive medication. Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TKI258 - Positive<br>These are the participants who had a positive T(4;14) status | Drug: TKI258<br>* All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.<br>* Other names: Dovitinib;|
| Experimental: TKI258 - Negative<br>These are the participants who had a negative T(4;14) status | Drug: TKI258<br>* All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.<br>* Other names: Dovitinib;|
| Experimental: TKI258 Non-interpretable<br>These are the participants who had a non-interpretable T(4;14) status | Drug: TKI258<br>* All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.<br>* Other names: Dovitinib;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete responses (CR) or partial response (PR) defined according to RECIST |  | Every 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Benefit (CR, PR and SD ≥ 24 weeks after start of study treatment), PFS |  | Every 8 weeks | 
| Safety and tolerability of TKI258 treatment assessed by frequency and severity of Adverse Events. |  | Monthly | 
| Pharmacokinetic: plasma concentrations and PK parameters (e.g. Cmax, Tmax, AUC0-t) |  | Study Day 1, 5 , 26, 52, 78 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer, HER2 negative, FGFR1